Mona Mohammed Abdelrahman
Sohag, Egypt
NCT Number: NCT04949412
his a prospective observational study will be conducted on 100 patients who were diagnosed as SARS-CoV2 positive. The data will be collected from isolation hospital in Sohag governorate during the period from the start of June 2021 to the end of July 2021. Patients will be followed up for at least one month to evaluate the prognosis.
Looking for future studies?
Notify MeAll sexes
Observational
Sohag, Egypt
This a prospective observational study will be conducted on 100 patients who were diagnosed as SARS-CoV2 positive. The data will be collected from isolation hospital in Sohag governorate during the period from the start of June 2021 to the end of July 2021. Patients will be followed up for at least one month to evaluate the prognosis.
Inclusion criteria
Patients with SARS-CoV2 positive PCR.
Exclusion criteria
Patients with chronic obstructive lung disease Chronic renal failure Patients with malabsorption Organ transplant recipient Pregnant women The study protocol will be approved by the scientific Research Ethical committee, Faculty of Medicine, Sohag University.
The Data will be collected after taken informed written consent from the patients:
Data about clinical manifestation including as fever, cough, dyspnea, fatigue and diarrhea.
Laboratory investigation:
CBC , liver function tests, CRP, D-dimer Serum creatinine, Random blood sugar, Serum ferritin and zwsVitamin D level
Assessment the severity of the disease:
Patients were classified into severe or mild cases based on results from chest radiography, clinical examination, and symptoms.
Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types. A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura.
Severe pneumonia was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR ≥30 times/minute; ii) hypoxia: oxygen saturation (resting state) ≤93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) ≤ 300 mmHg (millimeters of Mercury); or iv) the occurrence of respiratory or other organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock 6.
Statistical analysis:
Continuous variables were expressed as mean ± standard deviation or median and interquartile range and compared with the student's t-test or Mann-Whitney U test according to the distribution of data. Categorical variables were presented as numbers and percentages and compared using the chi squared test or the Fisher exact test as appropriate. Spearman P rho was used to assess the relationships between serum 25OHD levels and several clinical and laboratory parameters. P value will be considered significant if it was less than 0.05.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with SARS-CoV2 positive PCR
Exclusion criteria
Patients with chronic obstructive lung disease Chronic renal failure Patients with malabsorption Organ transplant recipient Pregnant women
serum vitamin D level
Time frame: during the period from the start of June 2021 to the end of July 2021
Sohag University
Other
Assessment of Serum Vitamin D Level in COVID-19 Infected Patients
Acronym: COVID19
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04747249
COVID-19, Coronaviridae Infections
Caen, France
View Trial DetailsNCT04924881
COVID-19, Coronaviridae Infections
Shatin, Hong Kong
View Trial DetailsNCT04939506
Behavior, COVID-19
New Orleans, Louisiana, United States
View Trial DetailsNCT04705116
COVID-19, Coronaviridae Infections
Los Angeles, California, United States
View Trial Details